As healthcare shifts toward precision medicine and data-driven care, continuous biochemical monitoring is emerging as a transformative frontier in both clinical medicine and biopharma development. Profusa is at the forefro... Read more
As biologics, advanced therapies, and specialised injectable medicines continue to reshape the pharmaceutical landscape, the demand for agile and highly compliant sterile manufacturing partners has never been greater. In this Biopharma Boardr... Read more
Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income from operations increased to EUR 241 million Adjusted EBITA margin increased 40 basis points t... Read more
As biologics manufacturing operations become increasingly complex, biopharma companies are under growing pressure to improve efficiency, strengthen contamination control and meet evolving regulatory expectations without compromising product q... Read more
Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income from operations increased to EUR 241 million Adjusted EBITA margin increased 40 basis points t... Read more
Financial performance Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US. Q1 2026 adjusted sales, excluding the 340B provision reversal, decreased... Read more
Creates Standalone Leader in Advanced Therapy Manufacturing with Decades of Proven Experience and Continued Commitment to Client Service Dedicated Resources and Backing from GI Partners to Drive Innovation and Introduce New Capabilities GI Partn... Read more
Hongene Biotech Corporation today announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end development and manufacturing solutions fo... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
